Analyst Yigal Nochomovitz from Citi maintained a Buy rating on Caribou Biosciences and keeping the price target at $8.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yigal Nochomovitz has given his Buy rating due to a combination of factors, including Caribou Biosciences’ advancing clinical pipeline and well-defined regulatory path. Management continues to work closely with the FDA on designing a pivotal Phase 2 trial for vispa-cel in second-line large B‑cell lymphoma, while longer-term data from the ongoing ANTLER Phase 1 trial are expected this year, which could further clarify efficacy and durability.
In addition, Caribou is progressing CB-011 in multiple myeloma, moving into the dose-expansion stage to evaluate both BCMA-naïve and previously BCMA-treated relapsed/refractory patients, with more mature data anticipated in 2026. The company ended the year with roughly $143 million in cash, which management believes should finance operations into the second half of 2027, supporting key clinical milestones; this funding runway, combined with substantial modeled upside to the $8 target price, underpins the High Risk/Buy stance.
Nochomovitz covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, Zenas BioPharma, Inc., and Arcus Biosciences. According to TipRanks, Nochomovitz has an average return of 2.1% and a 36.71% success rate on recommended stocks.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $6.00 price target.